Current Editions
Quantifying impact of accelerated approval on life extension
Study attributes over 260,000 additional life years in 2006-22 to accelerated approval
Regulation
Product Development
Clinical report: Academic trials signal autoimmune opportunities for T cell engagers
Plus: Results from Lilly’s Verzenio, antibody-drug conjugate Enhertu, and programs from Newron and Annovis
Emerging Company Profile
Enlaza: Creating covalent biologics using engineered amino acids
Avalon-incubated biotech now has $161M to advance what could be the first covalent, irreversible protein drugs, starting in oncology
Management Tracks
Innovent hires Gracell vet Samuel Zhang as CBO
Plus: CEO changes at Lexicon, Avacta and Sphere Fluidics, and updates from Generate, Charm, ViaNautis and more
BioCentury ISSN 1097-7201